中国卒中学会急性缺血性卒中再灌注治疗指南2024

doi:10.3969/j.issn.1673-5765.2024.12.014

摘要/Abstract

摘要： 近年来，急性缺血性卒中静脉溶栓和机械取栓领域的临床试验取得了显著进展，新的研究结果不断扩大静脉溶栓和机械取栓的适应证人群。基于研究进展，中国卒中学会急性缺血性卒中再灌注治疗指南2024编写组邀请我国卒中领域的专家，对现有的急性缺血性卒中再灌注治疗证据进行广泛讨论，形成了分级推荐意见。本次指南制定对静脉溶栓和机械取栓治疗的最新筛选标准进行了概述，并汇总了不同溶栓药物选择的现有证据，以期对急性缺血性卒中的再灌注治疗决策提供帮助。

关键词: 缺血性卒中; 脑血管病; 再灌注治疗; 机械取栓; 血管内治疗; 静脉溶栓

Abstract: Recently, significant progress has been made in clinical trials in the field of intravenous thrombolysis and mechanical thrombectomy for acute ischemic stroke. New research results continuously expanded the indications for both intravenous thrombolysis and mechanical thrombectomy. Based on these advancements, the Writing Group of Chinese Stroke Association Guidelines on Reperfusion Therapy for Acute Ischemic Stroke 2024 invited experts in the field of stroke in China to extensively discuss the existing evidence on reperfusion therapy for acute ischemic stroke, resulting in graded recommendations. This guideline outlines the latest screening criteria for intravenous thrombolysis and mechanical thrombectomy and summarizes the current evidence on different thrombolytic drug options, in order to provide a reference for decision-making on reperfusion therapy of acute ischemic stroke.

Key words: Ischemic stroke; Cerebrovascular disease; Reperfusion therapy; Mechanical thrombectomy; Endovascular treatment; Intravenous thrombolysis

中图分类号:

中国卒中学会, 《中国卒中学会急性缺血性卒中再灌注治疗指南》编写组. 中国卒中学会急性缺血性卒中再灌注治疗指南2024[J]. 中国卒中杂志, 2024, 19(12): 1460-1478.

Chinese Stroke Association, Writing Group of Chinese Stroke Association Guidelines on Reperfusion Therapy for Acute Ischemic Stroke . Chinese Stroke Association Guidelines on Reperfusion Therapy for Acute Ischemic Stroke 2024[J]. Chinese Journal of Stroke, 2024, 19(12): 1460-1478.

参考文献

[1] MA Q F，LI R，WANG L J，et al. Temporal trend and attributable risk factors of stroke burden in China，1990—2019：an analysis for the global burden of disease study 2019[J/OL]. Lancet Public Health，2021，6（12）：e897-e906[2024-10-28]. https://doi.org/10.1016/S2468-2667（21）00228-0.
[2] WANG W Z，JIANG B，SUN H X，et al. Prevalence，incidence，and mortality of stroke in China：results from a nationwide population-based survey of 480 687 adults[J]. Circulation，2017，135（8）：759-771.
[3] GOYAL M，MENON B K，VAN ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.
[4] HACKE W，KASTE M，BLUHMKI E，et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med，2008，359（13）：1317-1329.
[5] SANDERCOCK P，WARDLAW J M，LINDLEY R I，et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke（the third international stroke trial [IST-3]）：a randomised controlled trial[J]. Lancet，2012，379（9834）：2352-2363.
[6] EMBERSON J，LEES K R，LYDEN P，et al. Effect of treatment delay，age，and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke：a meta-analysis of individual patient data from randomised trials[J]. Lancet，2014，384（9958）：1929-1935.
[7] WARDLAW J M，MURRAY V，BERGE E，et al. Recombinant tissue plasminogen activator for acute ischaemic stroke：an updated systematic review and meta-analysis[J]. Lancet，2012，379（9834）：2364-2372.
[8] BIVARD A，ZHAO H，CHURILOV L，et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne mobile stroke unit（TASTE-A）：a phase 2，randomised，open-label trial[J]. Lancet Neurol，2022，21（6）：520-527.
[9] HALEY E C，Jr，THOMPSON J L P，GROTTA J C，et al. Phase ⅡB/Ⅲ trial of tenecteplase in acute ischemic stroke：results of a prematurely terminated randomized clinical trial[J]. Stroke，2010，41（4）：707-711.
[10] HUANG X Y，CHERIPELLI B K，LLOYD S M，et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke（ATTEST）：a phase 2，randomised，open-label，blinded endpoint study[J]. Lancet Neurol，2015，14（4）：368-376.
[11] KVISTAD C E，NÆSS H，HELLEBERG B H，et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway（NOR-TEST 2，part A）：a phase 3，randomised，open-label，blinded endpoint，non-inferiority trial[J]. Lancet Neurol，2022，21（6）：511-519.
[12] LOGALLO N，NOVOTNY V，ASSMUS J，et al. Tenecteplase versus alteplase for management of acute ischaemic stroke（NOR-TEST）：a phase 3，randomised，open-label，blinded endpoint trial[J]. Lancet Neurol，2017，16（10）：781-788.
[13] MENG X，LI S Y，DAI H G，et al. Tenecteplase vs. alteplase for patients with acute ischemic stroke：the ORIGINAL randomized clinical trial[J]. JAMA，2024，332（17）：1437-1445.
[14] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[15] MUIR K W，FORD G A，FORD I，et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset（ATTEST-2）：a randomised，parallel group，open-label trial[J]. Lancet Neurol，2024，23（11）：1087-1096.
[16] PARSONS M，SPRATT N，BIVARD A，et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2012，366（12）：1099-1107.
[17] PARSONS M W，YOGENDRAKUMAR V，CHURILOV L，et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke（TASTE）：a multicentre，randomised，controlled，phase 3 non-inferiority trial[J]. Lancet Neurol，2024，23（8）：775-786.
[18] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[19] CAMPBELL B C V，MITCHELL P J，CHURILOV L，et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke[J]. N Engl J Med，2018，378（17）：1573-1582.
[20] BURGOS A M，SAVER J L. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke：meta-analysis of 5 randomized trials[J]. Stroke，2019，50（8）：2156-2162.
[21] SMALLING R W，BODE C，KALBFLEISCH J，et al. More rapid，complete，and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction[J]. Circulation，1995，91（11）：2725-2732.
[22] NOBLE S，MCTAVISH D. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction[J]. Drugs，1996，52（4）：589-605.
[23] DEN HEIJER P，VERMEER F，AMBROSIONI E，et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction：a double-blind，randomized angiographic trial of lanoteplase versus alteplase[J]. Circulation，1998，98（20）：2117-2125.
[24] LI S Y，WANG X C，JIN A M，et al. Safety and efficacy of reteplase versus alteplase for acute ischemic stroke：a phase 2 randomized controlled trial[J]. Stroke，2024，55（2）：366-375.
[25] LI S Y，GU H Q，LI H，et al. Reteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2024，390（24）：2264-2273.
[26] LI S Y，GU H Q，FENG B Y，et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset（PROST-2）：a phase 3，open-label, non-inferiority，randomised controlled trial[J]. Lancet Neurol，2024（24）：00436-8[2024-11-29]. https://doi.org/10.1016/51474-4422（24）00436-8.
[27] DAVIS S M，DONNAN G A，PARSONS M W，et al. Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial（EPITHET）：a placebo-controlled randomised trial[J]. Lancet Neurol，2008，7（4）：299-309.
[28] RINGLEB P，BENDSZUS M，BLUHMKI E，et al. Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection[J]. Int J Stroke，2019，14（5）：483-490.
[29] MA H，CAMPBELL B C V，PARSONS M W，et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med，2019，380（19）：1795-1803.
[30] CAMPBELL B C V，MA H，RINGLEB P A，et al. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging：a systematic review and meta-analysis of individual patient data[J]. Lancet，2019，394（10193）：139-147.
[31] THOMALLA G，SIMONSEN C Z，BOUTITIE F，et al. MRI-guided thrombolysis for stroke with unknown time of onset[J]. N Engl J Med，2018，379（7）：611-622.
[32] KOGA M，YAMAMOTO H，INOUE M，et al. Thrombolysis with alteplase at 0.6 mg/kg for stroke with unknown time of onset：a randomized controlled trial[J]. Stroke，2020，51（5）：1530-1538.
[33] THOMALLA G，BOUTITIE F，MA H，et al. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging：systematic review and meta-analysis of individual patient data[J]. Lancet，2020，396（10262）：1574-1584.
[34] ROALDSEN M B，ELTOFT A，WILSGAARD T，et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT（TWIST）：a multicentre，open-label，randomised controlled trial[J]. Lancet Neurol，2023，22（2）：117-126.
[35] ALBERS G W，JUMAA M，PURDON B，et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection[J]. N Engl J Med，2024，390（8）：701-711.
[36] XIONG Y Y，CAMPBELL B C V，SCHWAMM L H，et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy[J]. N Engl J Med，2024，391（3）：203-212.
[37] CHENG X，HONG L，LIN L T，et al. Chinese acute tissue-based imaging selection for lysis in stroke tenecteplase Ⅱ（CHABLIS-T Ⅱ）：rationale and design[J/OL]. Stroke Vasc Neurol，2024：svn-2023-002890[2024-10-28]. https://doi.org/10.1136/svn-2023-002890.
[38] CAMPBELL B C V，MITCHELL P J，KLEINIG T J，et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med，2015，372（11）：1009-1018.
[39] GOYAL M，DEMCHUK A M，MENON B K，et al. Randomized assessment of rapid endovascular treatment of ischemic stroke[J]. N Engl J Med，2015，372（11）：1019-1030.
[40] JOVIN T G，CHAMORRO A，COBO E，et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke[J]. N Engl J Med，2015，372（24）：2296-2306.
[41] SAVER J L，GOYAL M，BONAFE A，et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med，2015，372（24）：2285-2295.
[42] BERKHEMER O A，FRANSEN P S S，BEUMER D，et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med，2015，372（1）：11-20.
[43] ALBERS G W，MARKS M P，KEMP S，et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging[J]. N Engl J Med，2018，378（8）：708-718.
[44] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct[J]. N Engl J Med，2018，378（1）：11-21.
[45] JOVIN T G，NOGUEIRA R G，LANSBERG M G，et al. Thrombectomy for anterior circulation stroke beyond 6 h from time last known well（AURORA）：a systematic review and individual patient data meta-analysis[J]. Lancet，2022，399（10321）：249-258.
[46] OLTHUIS S G H，PIRSON F A V，PINCKAERS F M E，et al. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography（MR CLEAN-LATE）in the Netherlands：a multicentre，open-label，blinded-endpoint，randomised，controlled，phase 3 trial[J]. Lancet，2023，401（10385）：1371-1380.
[47] BENDSZUS M，FIEHLER J，SUBTIL F，et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct：multicentre，open-label，randomised trial[J]. Lancet，2023，402（10414）：1753-1763.
[48] COSTALAT V，JOVIN T G，ALBUCHER J F，et al. Trial of thrombectomy for stroke with a large infarct of unrestricted size[J]. N Engl J Med，2024，390（18）：1677-1689.
[49] HUO X C，MA G T，TONG X，et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med，2023，388（14）：1272-1283.
[50] SARRAJ A，HASSAN A E，ABRAHAM M G，et al. Trial of endovascular thrombectomy for large ischemic strokes[J]. N Engl J Med，2023，388（14）：1259-1271.
[51] YOSHIMURA S，SAKAI N，YAMAGAMI H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.
[52] YOO A J，ZAIDAT O O，SHETH S A，et al. Thrombectomy for stroke with large infarct on noncontrast CT：the TESLA randomized clinical trial[J]. JAMA，2024，332（16）：1355-1366.
[53] CHEN H W，COLASURDO M. Endovascular thrombectomy for large ischemic strokes：meta-analysis of six multicenter randomized controlled trials[J/OL]. J Neurointerv Surg，2024：jnis-2023-021366[2024-10-28]. https://doi.org/10.1136/jnis-2023-021366.
[54] SUZUKI K，MATSUMARU Y，TAKEUCHI M，et al. Effect of mechanical thrombectomy without vs. with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke：the SKIP randomized clinical trial[J]. JAMA，2021，325（3）：244-253.
[55] ZI W J，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs. intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.
[56] FISCHER U，KAESMACHER J，STRBIAN D，et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke：an open-label，blinded-outcome，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：104-115.
[57] MITCHELL P J，YAN B，CHURILOV L，et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset：an open-label，blinded-endpoint，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：116-125.
[58] LECOUFFE N E，KAPPELHOF M，TREURNIET K M，et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med，2021，385（20）：1833-1844.
[59] YANG P F，ZHANG Y W，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.
[60] MAJOIE C B，CAVALCANTE F，GRALLA J，et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke：individual participant data meta-analysis of six randomised trials[J]. Lancet，2023，402（10406）：965-974.
[61] LIU X F，DAI Q L，YE R D，et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion（BEST）：an open-label，randomised controlled trial[J]. Lancet Neurol，2020，19（2）：115-122.
[62] JOVIN T G，LI C H，WU L F，et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1373-1384.
[63] LANGEZAAL L C M，VAN DER HOEVEN E J R J，MONT’ALVERNE F J A，et al. Endovascular therapy for stroke due to basilar-artery occlusion[J]. N Engl J Med，2021，384（20）：1910-1920.
[64] TAO C R，NOGUEIRA R G，ZHU Y Y，et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1361-1372.
[65] ADUSUMILLI G，KOBEISSI H，GHOZY S，et al. Endovascular thrombectomy after acute ischemic stroke of the basilar artery：a meta-analysis of four randomized controlled trials[J/OL]. J Neurointerv Surg，2023，15（e3）：e446-e451[2024-10-28]. https://doi.org/10.1136/jnis-2022-019776.
[66] SCHWAMM L H，FONAROW G C，REEVES M J，et al. Get with the guidelines-stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack[J]. Circulation，2009，119（1）：107-115.
[67] SAVER J L，FONAROW G C，SMITH E E，et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke[J]. JAMA，2013，309（23）：2480-2488.
[68] XIAN Y，SMITH E E，ZHAO X，et al. Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke[J]. Stroke，2014，45（5）：1387-1395.
[69] FONAROW G C，ZHAO X，SMITH E E，et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative[J]. JAMA，2014，311（16）：1632-1640.
[70] MAN S M，XIAN Y，HOLMES D N，et al. Association between thrombolytic door-to-needle time and 1-year mortality and readmission in patients with acute ischemic stroke[J]. JAMA，2020，323（21）：2170-2184.
[71] XIAN Y，HOLLOWAY R G，CHAN P S，et al. Association between stroke center hospitalization for acute ischemic stroke and mortality[J]. JAMA，2011，305（4）：373-380.
[72] GU H Q，YANG X，WANG C J，et al. Clinical characteristics，management，and in-hospital outcomes in patients with stroke or transient ischemic attack in China[J/OL]. JAMA Netw Open，2021，4（8）：e2120745[2024-10-19]. https://pubmed.ncbi.nlm.nih.gov/34387677/.
[73] ZHONG W S，LIN L T，GONG X X，et al. Evaluation of a multicomponent intervention to shorten thrombolytic door-to-needle time in stroke patients in China（mission）：a cluster-randomized controlled trial[J/OL]. PLoS medicine，2022，19（7）：e1004034[2024-10-19]. https://doi.org/10.1371/journal.pmed.1004034.
[74] WANG C J，GU H Q，ZONG L X，et al. Effectiveness of a quality improvement intervention on reperfusion treatment for patients with acute ischemic stroke：a stepped-wedge cluster randomized clinical trial[J/OL]. JAMA Netw Open，2023，6（6）：e2316465[2024-10-19]. https://doi.org/10.1001/jamanetworkopen.2023.16465.